



Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Regd. Off : 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh. Phone : +91 98846 24100

To
BSE Limited
Phiroze Jeejeebhoy Towers
21st Floor, Dalal Street
Mumbai – 400 001

November 14, 2024

BSE Scrip Code: 524322

Subject: Statement of Deviation or Variation of funds under Regulation 32 of SEBI (LODR) Regulations, 2015

Sir,

Pursuant to Regulation 32 of the SEBI (LODR) Regulations, 2015 please note that there are no deviation(s) or variation (s) in respect of the utilization of the proceeds of the Preferential allotment of 56,90,500 equity shares of the company during the quarter ended 30 September 2024 as mentioned in the purpose and object of the offer. Please find enclosed herewith a statement in this regard

The aforesaid statement have been reviewed by Audit Committee and taken on record by the Board at their Board meeting held on 14.11.2024

Thanking you,

Yours sincerely,

For Kabra Drugs Limited



Managing Director

DIN:01895602



Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Regd. Off : 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh. Phone : +91 98846 24100

STATEMENT OF DEVIATION OR VARIATIO IN UTILIZATION OF FUNDS RAISED	
Name of listed entity	KABRA DRUGS LIMITED
Mode of Fund Raising	Preferential Issues
Date of Raising Funds	05-07-2024
Amount Raised (in Rs. Crores)	5.69
Report filed for Quarter ended	30-09-2024
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	Not applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not applicable
If Yes, Date of shareholder Approval	Not applicable
Explanation for the Deviation / Variation	Not applicable
Comments of the Audit Committee after review	None
Comments of the auditors, if any	None

Objects for which funds have been raised and where there has been a deviation, in the following table

Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
Issue of 56,90,500 Equity Shares to Strategic Investors (being Non-Promoters) on Preferential allotment basis is being made for cash with the object of meeting the working capital requirements, and general corporate purposes in order to support the future growth plan of the Company	NO	5690500	NO	5690500	NO	NO



N.ARAVIND
MANAGING DIRECTOR
DIN:01895602